Bioregulators
The compounds of endogenic pharmacology — short peptide bioregulators of the Khavinson lineage and proprietary acetylated, amidated analogs.
What constitutes a bioregulator.
A bioregulator is a regulatory molecule — most commonly a short peptide of two to seven amino acids — that participates in the body's endogenous regulatory architecture. Bioregulators act in nanomolar concentrations, translocate to the nucleus, bind specific DNA sequences, and modulate gene expression in a tissue-specific manner.
The class includes both endogenously-occurring sequences and their engineered analogs. They are biodegradable, do not bioaccumulate, and act through native regulatory pathways rather than through receptor blockade or pathway override.
The canon, and the proprietary extension.
The therapeutic class divides into two subclasses. The Khavinson lineage is the canonical foundation — four decades of institutional research. The proprietary trade-named portfolio — Telogenix™, Thymogenix™, Vasogenix™, Dermogenix™, Cortigenix™, Lymphogenix™, and Gonadogenix™ — is the proprietary extension that makes the canon deliverable through non-injectable routes.
The Khavinson lineage.
Across four decades of peer-reviewed research, short peptides of two to seven amino acids emerged as the privileged mechanism for tissue-specific gene regulation. Characterized across cell culture, in-vivo mammalian models, and human clinical study.
Each peptide acts predominantly within the tissue or system from which its parent regulatory sequence originated.
- AEDGPineal axis · circadian regulation
- EDRVascular endothelium
- KEThymic / immune competence
- KEDVascular and cardiovascular
- GHKConnective tissue · skin remodeling
- VAGCardiac and vascular
- AEDThymus · cellular immunity
- KEDWPancreatic / metabolic regulation
Trade-named bioregulator modified.
The native short peptides are rapidly cleaved by amino- and carboxypeptidases, restricting them historically to injection. Acetylation of the N-terminus and amidation of the C-terminus preserves regulatory activity while enabling formulation across topical, transdermal, intranasal, sublingual, and oral routes.
Patent-pending compositions of matter. Representative portfolio; full set includes additional compositions and method-of-use claims.
- TelogenixPineal / circadian / telomerase
- CortigenixCognition / neuroprotection
- LymphogenixLymphoid / mucosal immunity
- ThymogenixThymic restoration / T-cell competence
- VasogenixEndothelial / anti-atherogenic
- ImmunogenixThymus / cellular immunity
- PancreagenixPancreatic / metabolic regulation
Five non-injectable routes.
The proprietary modification enables therapeutic-grade bioregulator delivery across topical (creams, serums, transdermal patches), intranasal (sprays, drops), sublingual (troches, sprays, dissolvable films), oral (capsules, controlled-release oral preparations), and transdermal (extended-release patches) routes. Each format is matched to the target tissue, the therapeutic indication, and the pharmacokinetic profile required.